Register Log-in Investor Type

News

18 Jul 2019

Silence stock jumps on Mallinckrodt deal

Silence stock jumps on Mallinckrodt deal – UK biotech Silence Therapeutics saw its stock jump by 60% this morning on the back of a licensing deal, R&D collaboration and equity investment from the Irish-domiciled, US-based speciality pharmaceutical group Mallinckrodt. The overall deal has a “biodollar” or headline value exceeding $2.1bn, although initially it provides an upfront […]

16 Jul 2019

Scottish Mortgage leads $121m round in AI-based biotech Recursion

Scottish Mortgage leads $121m round in AI-based biotech Recursion – Baillie Gifford-managed Scottish Mortgage lnvestment Trust (SMT) has led a $121m Series C private financing in Recursion Pharmaceuticals, a US-based company that combines automated experimental biology with artificial intelligence tools. The financing brought in three new institutional investors – Intermountain Ventures, University of Minnesota, Texas […]

15 Jul 2019

Trust favourite Gilead expands R&D deal with Galapagos

Trust favourite Gilead expands R&D deal with Galapagos – US biotech giant Gilead Sciences (NASDAQ: GILD) has entered into a ten-year R&D collaboration with  Galapagos (Euronext/NASDAQ: GLPG) covering rights to the Belgium group’s entire development portfolio. The transformative deal includes a $3.95bn upfront payment – a new record in the industry – as well as $1.1bn in […]

09 Jul 2019

Shield poised for FDA decision on Feraccru for anemia

Shield poised for FDA decision on Feraccru for anemia – Shield Therapeutics (STX) should hear at some point over the next two weeks whether the FDA will approve its oral iron supplement Ferracru for treatment of iron deficiency. The decision, due by 26 July, is of course important but is further complicated by a statistical issue with the […]

09 Jul 2019

Morphosys takes option on Vivoryon’s QPCTL inhibitors in oncology

Morphosys takes option on Vivoryon’s QPCTL inhibitors in oncology – Germany’s Morphosys (MOR) has taken up an option to license Vivoryon’s family of inhibitors of the glutaminyl-peptide cyclotransferase-like (QPCTL) protein in oncology, in exchange for a commitment to invest €15m as part of a capital raising planned for later this year. The option covers Vivoryon’s lead compound […]

08 Jul 2019

Y-mAbs confirms plans to start naxitamab filing in November

Y-mAbs confirms plans to start naxitamab filing in November  – HBM-investee Y-mAbs Therapeutics (YMAB) has confirmed plans to start a rolling US filing for naxitamab for the treatment of patients its with relapsed/refractory high-risk neuroblastoma in November, after a pre-BLA meeting with the FDA. The company aims to file the clinical/safety and non-clinical portions of […]

08 Jul 2019

4D Pharma starts first trial in asthma

4D Pharma starts first trial in asthma – UK microbiome biotech 4D Pharma  (DDDD) has started a clinical trial of a live biotherapeutic, MRx-4DP000, in asthma, the first time such a drug concept has been tested in this condition. The double-blind, placebo-controlled Phase I/II study will enrol 90 patients whose asthma is inadequately controlled on inhaled therapy. Patients will […]

04 Jul 2019

Cantargia aims for first results of key study in Q4

Cantargia aism for first results of key study in Q4 – Sweden’s Cantargia (CANT) expects to report the first efficacy data from lead product nidanilimab in the fourth quarter of this year, some months earlier than expected, after quickly reaching its target recruitment of 20 patients – six with non-small cell lung cancer (NSCLC)  and […]

04 Jul 2019

FDA surprises with controversial OK for Karyopharm’s selinexor

FDA surprises with controversial OK for Karyopharm’s selinexor  – US Biotech Karyopharm Therapeutics (Nasdaq:KPTI) saw its stock jump 36% yesterday on news that the FDA has granted an accelerated approval to its anticancer Xpovo (selinexor), a nuclear export inhibitor, for late-line relapsed or refractory multiple myeloma (RRMM). The news surprised many specialist investors as the application […]

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…